Late radiation side effects after postoperative IMRT and brachytherapy for cervical and endometrial cancer
Official title: Assessment of Late Gastrointestinal and Genitourinary Toxicities in Cervical and Endometrial Cancer Requiring Postoperative IMRT and/or Brachytherapy
Run by Tata Memorial Hospital · NCT07435623 · Data updated 2026-11-12
This project will see how often and how severe late gastrointestinal and urinary side effects are in people with cervical or endometrial cancer who received postoperative IMRT and/or brachytherapy at Tata Memorial Hospital.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | Women only |
| Enrollment | 300 (estimated) |
| Sponsor | Tata Memorial Hospital Government |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Mumbai, Maharashtra) |
| Status | Recruiting |
| Started | May 10, 2025 |
| Main results expected | July 10, 2025 |
| Study ends | August 25, 2026 |
| Registry record updated | March 2, 2026 |
| Trial ID | NCT07435623 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (>18) with confirmed cervical or endometrial cancer who completed adjuvant IMRT and/or brachytherapy at Tata Memorial Center and have available follow-up records.
✕Probably not a fit
Patients treated elsewhere, those with incomplete treatment details, residual disease, postoperative recurrences, immunosuppression, or who are lost to follow-up are unlikely to be included or to benefit from the findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational review will collect treatment and follow-up information for adults with confirmed cervical or endometrial cancer who received adjuvant IMRT and/or brachytherapy at Tata Memorial Center (TMH/ACTREC). Patients with incomplete treatment details, residual disease after surgery, postoperative recurrences, immunosuppressive disorders, or missing follow-up will be excluded. Investigators will analyze clinical records, toxicity grading, imaging, and follow-up visits to characterize late gastrointestinal and genitourinary toxicities after postoperative radiotherapy. The analysis aims to describe timing, severity, and potential risk factors for late toxicities in this single-center Indian cohort.
Why it matters
Potential benefit: If successful, the findings could help clinicians better counsel patients, tailor follow-up, and modify treatment planning to reduce late bowel and bladder side effects.
How similar studies have gone: Previous work has shown that IMRT can reduce some pelvic radiation toxicities compared with older techniques, but detailed data on late side effects after postoperative IMRT combined with brachytherapy—especially from Indian cohorts—are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients more than 18 years of age at the time of diagnosis. * All patients with confirmed histological diagnosis of cervical or endometrial cancer. * Only those patients who have received adjuvant (chemo)radiotherapy with IMRT and/or brachytherapy at TMH/ACTREC will be included. * Patients whose follow up information available Exclusion Criteria: * Patients with incomplete treatment details. * Patient having residual disease post-surgery. * Patient treated for post-operative recurrences. * Patient who lost to follow up. * Patients with Immunosuppressive disorder
Where it's running
-
Tata Memorial Center
Mumbai, Maharashtra, India Recruiting
Study contacts
- Study coordinator: Supriya Chopra
- Email: supriyasastri@gmail.com
- Phone: 02227405000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Shorter pelvic radiotherapy after surgery for cervical or endometrial cancer
A randomized study tests whether a shorter course of postoperative whole-pelvic radiotherapy can be as safe and effective as the standard longer schedule for women with cervical or endometrial cancer.
-
Evaluating the role of advanced imaging in gynecological cancers
This study is testing if advanced imaging techniques can help doctors better diagnose and treat women with cervical, endometrial, and ovarian cancers.
-
Personalized navigation to support rural and Black women with endometrial cancer
This pilot tests a tailored patient-navigation program to help rural and Black patients with endometrial cancer access care and services.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy
This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.